{"doc_id": "33629384", "type of study": "Therapy", "title": "", "abstract": "A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients.\nZinc inhibits replication of the SARS-CoV virus.\nWe aimed to evaluate the safety, feasibility, and biological effect of administering high-dose intravenous zinc (HDIVZn) to patients with COVID-19.\nWe performed a Phase IIa double-blind, randomized controlled trial to compare HDIVZn to placebo in hospitalized patients with COVID-19.\nWe administered trial treatment per day for a maximum of 7 days until either death or hospital discharge.\nWe measured zinc concentration at baseline and during treatment and observed patients for any significant side effects.\nFor eligible patients, we randomized and administered treatment to 33 adult participants to either HDIVZn (n\u2009=\u200915) or placebo (n\u2009=\u200918).\nWe observed no serious adverse events throughout the study for a total of 94 HDIVZn administrations.\nHowever, three participants in the HDIVZn group reported infusion site irritation.\nMean serum zinc on Day 1 in the placebo, and the HDIVZn group was 6.9\u2009\u00b1\u20091.1 and 7.7\u2009\u00b1\u20091.6\u2009\u00b5mol/l, respectively, consistent with zinc deficiency.\nHDIVZn, but not placebo, increased serum zinc levels above the deficiency cutoff of 10.7\u2009\u00b5mol/l (p\u2009<\u2009.001) on Day 6.\nOur study did not reach its target enrollment because stringent public health measures markedly reduced patient hospitalizations.\nHospitalized COVID-19 patients demonstrated zinc deficiency.\nThis can be corrected with HDIVZn.\nSuch treatment appears safe, feasible, and only associated with minimal peripheral infusion site irritation.\nThis pilot study justifies further investigation of this treatment in COVID-19 patients.\n\u00a9 2021 Wiley Periodicals LLC.\n", "Evidence Map": {"Enrollment": [{"term": "hospitalized COVID-19", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 126}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 112}, {"term": "Hospitalized COVID-19", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 21}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients .", "Evidence Elements": {"Participant": [{"term": "hospitalized COVID-19", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 126}], "Intervention": [{"term": "high-dose intravenous zinc", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 101}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 27}, {"term": "feasibility", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 43}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Zinc inhibits replication of the SARS-CoV virus .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Zinc", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 4}], "Outcome": [{"term": "replication of the SARS-CoV virus", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 47}], "Observation": [{"term": "inhibits", "negation": "affirmed", "UMLS": {}, "start": 5, "end": 13}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "We aimed to evaluate the safety , feasibility , and biological effect of administering high-dose intravenous zinc ( HDIVZn ) to patients with COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "high-dose intravenous zinc ( HDIVZn )", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 124}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 31}, {"term": "feasibility", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 45}, {"term": "biological effect", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 69}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "We performed a Phase IIa double-blind , randomized controlled trial to compare HDIVZn to placebo in hospitalized patients with COVID-19 .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 112}], "Intervention": [{"term": "HDIVZn", "negation": "affirmed", "UMLS": {}, "start": 79, "end": 85}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 96}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "We administered trial treatment per day for a maximum of 7 days until either death or hospital discharge .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "trial treatment", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 31}], "Outcome": [{"term": "death", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 82}, {"term": "hospital discharge", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 104}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "We measured zinc concentration at baseline and during treatment and observed patients for any significant side effects .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "zinc concentration", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 30}, {"term": "significant side effects", "negation": "affirmed", "UMLS": {}, "start": 94, "end": 118}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "For eligible patients , we randomized and administered treatment to 33 adult participants to either HDIVZn ( n = 15 ) or placebo ( n = 18 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "HDIVZn", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 106}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 121, "end": 128}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "We observed no serious adverse events throughout the study for a total of 94 HDIVZn administrations .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "HDIVZn", "negation": "negated", "UMLS": {}, "start": 77, "end": 83}], "Outcome": [{"term": "serious adverse events", "negation": "negated", "UMLS": {}, "start": 15, "end": 37}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "However , three participants in the HDIVZn group reported infusion site irritation .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "HDIVZn", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 42}], "Outcome": [{"term": "infusion site", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 71}], "Observation": [], "Count": [{"term": "three participants", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 28}]}, "Evidence Propositions": [{"Intervention": "HDIVZn", "Observation": "", "Count": "three participants", "Outcome": "infusion site"}]}, {"Section": "UNKNOWN", "Text": "Mean serum zinc on Day 1 in the placebo , and the HDIVZn group was 6.9 \u00b1 1.1 and 7.7 \u00b1 1.6 \u00b5mol / l , respectively , consistent with zinc deficiency .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 39}, {"term": "HDIVZn", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 56}], "Outcome": [{"term": "Mean serum zinc", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 15}], "Observation": [{"term": "6.9 \u00b1 1.1", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 76}, {"term": "7.7 \u00b1 1.6", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 90}, {"term": "l", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 34}], "Count": []}, "Evidence Propositions": [{"Intervention": "placebo", "Observation": "6.9 \u00b1 1.1", "Outcome": "Mean serum zinc", "Count": ""}, {"Intervention": "HDIVZn", "Observation": "6.9 \u00b1 1.1", "Outcome": "Mean serum zinc", "Count": ""}, {"Intervention": "HDIVZn", "Observation": "7.7 \u00b1 1.6", "Outcome": "Mean serum zinc", "Count": ""}, {"Intervention": "HDIVZn", "Observation": "l", "Outcome": "Mean serum zinc", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "HDIVZn , but not placebo , increased serum zinc levels above the deficiency cutoff of 10.7 \u00b5mol / l ( p < .001 ) on Day 6 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "HDIVZn", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}, {"term": "placebo", "negation": "negated", "UMLS": {}, "start": 17, "end": 24}], "Outcome": [{"term": "serum zinc levels above the deficiency cutoff of 10.7", "negation": "negated", "UMLS": {}, "start": 37, "end": 90}], "Observation": [{"term": "increased", "negation": "negated", "UMLS": {}, "start": 27, "end": 36}, {"term": "l", "negation": "negated", "UMLS": {}, "start": 18, "end": 19}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Our study did not reach its target enrollment because stringent public health measures markedly reduced patient hospitalizations .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "stringent public health measures", "negation": "negated", "UMLS": {}, "start": 54, "end": 86}], "Outcome": [{"term": "patient hospitalizations", "negation": "negated", "UMLS": {}, "start": 104, "end": 128}], "Observation": [{"term": "reduced", "negation": "negated", "UMLS": {}, "start": 96, "end": 103}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Hospitalized COVID-19 patients demonstrated zinc deficiency .", "Evidence Elements": {"Participant": [{"term": "Hospitalized COVID-19", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 21}], "Intervention": [], "Outcome": [{"term": "zinc deficiency", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 59}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "This can be corrected with HDIVZn .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Such treatment appears safe , feasible , and only associated with minimal peripheral infusion site irritation .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "This pilot study justifies further investigation of this treatment in COVID-19 patients .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "\u00a9 2021 Wiley Periodicals LLC .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}